A Case of Idiopathic Intracranial Hypertension with Papilledema Secondary to Recombinant Human Growth Hormone Treatment
10.3341/jkos.2022.63.8.735
- Author:
Hyun SUH
1
;
Sun Young SHIN
;
Shin Hae PARK
Author Information
1. Department of Ophthalmology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:Case Report
- From:Journal of the Korean Ophthalmological Society
2022;63(8):735-739
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To report a child with idiopathic intracranial hypertension secondary to recombinant human growth hormone treatment.Case summary: An 11-year-old girl presented with blurred vision in both eyes starting 6 weeks earlier. She did not have any underlying disease and her body mass index was normal. She had started recombinant human growth hormone injections for idiopathic short stature 3 months earlier. The best corrected visual acuity was 20/25 in both eyes. Fundoscopy revealed bilateral disc edema with peripapillary hemorrhage and increased tortuosity of the retinal vessels. Bilateral enlargement of the blind spot was found on automated visual field examination. Magnetic resonance imaging and venography of the brain showed no evidence of structural or vascular lesions related to increased intracranial pressure. A lumbar puncture showed an elevated opening pressure of 26 cmH2O with normal cerebrospinal fluid constituents. She was diagnosed with growth hormone-related idiopathic intracranial hypertension and it was recommended that the growth hormone injection be discontinued and oral acetazolamide started. After 4 weeks of treatment, the optic disc edema and visual field defect improved. At the 2-year follow-up, she had a normal visual field with a normal optic nerve in both eyes.
Conclusions:Ophthalmologists should be aware of the clinical features and treatment of idiopathic intracranial hypertension secondary to recombinant human growth hormone treatment, which is a very rare, vision-threatening complication. Complete neuro-ophthalmological examinations should be performed immediately in children complaining of visual disturbances or headache during treatment with recombinant human growth hormone.
